跳至主要内容
临床试验/NCT02694172
NCT02694172已完成不适用

Analysis of the Diversity of Faecal Bacteria in Healthy and Type 2 Diabetic Subjects

Société des Produits Nestlé (SPN)0 个研究点目标入组 67 人开始时间: 2007年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
67
主要终点
Fecal microbiota profile

研究概览

简要总结

The main objective of the clinical trial is to investigate whether overweight type 2 diabetic patients have a different fecal microbiota profile compared with age, gender, BMI matched subjects and with lean healthy subjects before and after the consumption of fiber rich cereal bars.

详细描述

Gut microbiota refers to the bacterial communities in the gastrointestinal tract. The diversity and quantity of bacteria vary depending on age of the individuals, daily diet and the segment of the intestine, which makes the gut microbiota one of the most complex bacterial ecosystems known to men. In general, over trillions of bacteria reside in human gut. Recent evidence indicates that gut microbiota could be involved in host metabolism by multiple pathways leading to the development of obesity and type 2 diabetes. Increased fat storage or obesity has become one of the leading public health issues in many developed and developing countries. However, it is not clear whether type 2 diabetes is associated with a unique gut microbiota profile. Therefore, the primary objective of the study is to compare the fecal microbiota of overweight type 2 diabetic subjects to that of age, gender and BMI matched subjects as well as with lean non-diabetic subjects. In addition, the investigators hypothesize that microbiota modifications with consumption of fiber rich food products can improve the metabolic outcomes of type 2 diabetics. To test this hypothesis, the investigators plan to provide each overweight participant with two cereal bars per day for 4 weeks. Anthropometric measurements and plasma parameters as well as the fecal microbiota will be determined.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
30 Years 至 55 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •All diabetic and control non-diabetic subjects (of same BMI) must comply with all the following inclusion criteria:
  • •Ethnic background: Caucasian
  • •BMI: 25 to 40 kg/m2
  • •Fasting blood glucose > 7 mmol/L
  • •Fasting Hemoglobin A1c > 7%
  • •Consume mainly typical Western diets daily
  • •Having obtained his/her informed consent
  • •Lean non-diabetic healthy subjects must comply with the following inclusion criteria:
  • •Ethnic background: Caucasian
  • •BMI: 20 to 25 kg/m2
  • •Fasting blood glucose < 5.5 mmol/L
  • •Fasting Hemoglobin A1c < 6 %
  • •Consume mainly typical Western diets daily
  • •Having obtained his/her informed consent

排除标准

  • •Diabetic and healthy (same BMI) subjects representing one or more of the following criteria are excluded from participation in the study.
  • •Dietary supplements or medications known to alter gut bacteria, such as antibiotic medication or intestinal transit modulators
  • •People actively take cortisol or dexamethasone should be excluded from the study
  • •People under a-amylase/a-glucosidase inhibitors should be excluded from the study. However, patients under metformin can be accepted for this study.
  • •Patients under metformin suffering from gastrointestinal side effects within a 6-month time period prior to the trial
  • •Regular consumption of fermented dairy products
  • •Vegetarians
  • •Frequent diarrhea (more than two loose stool per day) within 7 days before the enrollment
  • •HIV seropositive
  • •Having known gastrointestinal diseases such as ulcerative colitis, Crohn's disease, peptic ulcers and cancer
  • •Patients who cannot be expected to comply with treatment
  • •Currently participating or having participated in another clinical trial during the last 6 months prior to the beginning of this study
  • •Females with hormone therapy will be excluded from the study
  • •Lean healthy subjects representing one or more of the following criteria are excluded from participation in the study.
  • •Dietary supplements or medications known to alter gut bacteria, such as antibiotic medication or intestinal transit modulators
  • •Regular consumption of fermented dairy products
  • •Vegetarians
  • •Frequent diarrhea (more than two loose stool per day) within 7 days before the enrollment
  • •HIV seropositive
  • •Having known gastrointestinal diseases such as ulcerative colitis, Crohn's disease, peptic ulcers and cancer
  • •Patients who cannot be expected to comply with treatment
  • •Currently participating or having participated in another clinical trial during the last 6 months prior to the beginning of this study
  • •Females with hormone therapy will be excluded from the study

研究组 & 干预措施

Lean non diabetic

No Intervention

Lean and healthy subjects receiving no intervention

Overweight non diabetic

Experimental

fiber rich cereal bars, two bars a day for 4 weeks

干预措施: Fiber rich cereal bars (Other)

Overweight diabetic

Experimental

fiber rich cereal bars, two bars a day for 4 weeks

干预措施: Fiber rich cereal bars (Other)

结局指标

主要结局

Fecal microbiota profile

时间窗: Baseline samples taken after 2 weeks of diet normalization period

Fecal samples taken after the two week diet normalization are subjected to bacteria 16S rDNA sequencing and by quantitative PCR.

次要结局

  • Plasma triglycerides(Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable)
  • Plasma total cholesterol(Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable)
  • Metabonomic analysis in faeces(Samples taken after 2 weeks of diet normalization period (baseline) and 4 weeks of cereal bars intake when applicable)
  • Metabonomic analysis in plasma(Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable)
  • Metabonomic analysis in urine(Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable)
  • Plasma glucose(Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable)
  • Plasma insulin(Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable)
  • Plasma free fatty acids(Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable)
  • Plasma HDL cholesterol(Samples taken after 2 weeks of diet normalization period and 4 weeks of cereal bars intake when applicable)

研究者

发起方
Société des Produits Nestlé (SPN)
申办方类型
Industry
责任方
Sponsor

相似试验